<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>OPUS 4 Latest Documents RSS Feed</title>
    <description>Latest documents</description>
    <link>http://publikationen.ub.uni-frankfurt.de/index/index/</link>
    <pubDate>Wed, 19 Aug 2009 14:04:18 +0200</pubDate>
    <lastBuildDate>Wed, 19 Aug 2009 14:04:18 +0200</lastBuildDate>
    <item>
      <title>IFN-gamma impairs release of IL-8 by IL-1beta-stimulated A549 lung carcinoma cells</title>
      <link>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/6766</link>
      <description>Background Production of interferon (IFN)-gamma is key to efficient anti-tumor immunity. The present study was set out to investigate effects of IFNgamma on the release of the potent pro-angiogenic mediator IL-8 by human A549 lung carcinoma cells. &#13;
Methods A549 cells were cultured and stimulated with interleukin (IL)-1beta alone or in combination with IFNgamma. IL-8 production by these cells was analyzed with enzyme linked immuno sorbent assay (ELISA). mRNA-expression was analyzed by real-time PCR and RNase protection assay (RPA), respectively. Expression of inhibitor-kappaBalpha, cellular IL-8, and cyclooxygenase-2 was analyzed by Western blot analysis. &#13;
Results Here we demonstrate that IFNgamma efficiently reduced IL-8 secretion under the influence of IL-1beta. Surprisingly, real-time PCR analysis and RPA revealed that the inhibitory effect of IFNgamma on IL-8 was not associated with significant changes in mRNA levels. These observations concurred with lack of a modulatory activity of IFNgamma on IL-1beta-induced NF-kappaB activation as assessed by cellular IkappaB levels. Moreover, analysis of intracellular IL-8 suggests that IFNgamma modulated IL-8 secretion by action on the posttranslational level. In contrast to IL-8, IL-1beta-induced cyclooxygenase-2 expression and release of IL-6 were not affected by IFNgamma indicating that modulation of IL-1beta action by this cytokine displays specificity. &#13;
Conclusions Data presented herein agree with an angiostatic role of IFNgamma as seen in rodent models of solid tumors and suggest that increasing T helper type 1 (Th1)-like functions in lung cancer patients e.g. by local delivery of IFNgamma may mediate therapeutic benefit via mechanisms that potentially include modulation of pro-angiogenic IL-8.</description>
      <author>Kim Alexander Boost; Christian David Sadik; Malte Bachmann; Bernhard Zwissler; Josef Martin Pfeilschifter; Heiko Mühl</author>
      <category>article</category>
      <guid>http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/6766</guid>
      <pubDate>Wed, 19 Aug 2009 14:04:18 +0200</pubDate>
    </item>
  </channel>
</rss>
